17
Participants
Start Date
May 8, 2020
Primary Completion Date
April 22, 2021
Study Completion Date
April 22, 2021
Botulinum toxin(Botox)
This study will evaluate the use of botulinum toxin for reduced oral aperture in scleroderma patients. Botox is a neurotoxin that functions as a paralytic by preventing the release of acetylcholine to inhibit muscle contracture and decrease fibrosis by decreasing differentiation of fibroblasts to myofibroblasts, decreasing expression of collagen, and increasing expression of matrix metalloproteinase.
UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials, Dallas
University of Texas Southwestern Medical Center
OTHER